Market Report Q312
Capital Flows Freely into Biotech Driven by Market Performance
By Peter Winter
Monday, October 8, 2012
Despite the continuing turbulence in the global capital markets, investors have had no qualms about backing the biotech sector more in public biotechs than in private ones, however.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.